April 29, 2024Thrombosis and Haemostasis
Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2
Authors
Discussion
Loading...
Member takes
Implication
Multicenter registry study finds similar thrombosis recurrence but lower bleeding with rivaroxaban in active cancer, indicating distinct direct oral anticoagulant safety profiles.
Key Points
- Recurrent venous thromboembolism and all-cause mortality risks did not differ significantly among patients receiving edoxaban, rivaroxaban, or apixaban over five years.
- Major bleeding occurred in 14.0% of rivaroxaban recipients compared with 22.6% of edoxaban recipients, demonstrating significantly reduced hemorrhage over five years.
- Analysis of registry records across 31 Japanese centers highlights that rivaroxaban may reduce bleeding hazards without compromising cancer-associated venous thromboembolism control.
Cite This Study
Sueta et al. (2024) studied this question.